If Artemisinin Drugs Fail, What's Plan B?

See allHide authors and affiliations

Science  14 May 2010:
Vol. 328, Issue 5980, pp. 846
DOI: 10.1126/science.328.5980.846

You are currently viewing the summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution


If the current generation of artemisinin-based combination therapies (ACTs) should fail, does the world have a solid backup plan? The short answer: No. New funding has lured academics and pharmaceutical companies back to the malaria field after a decades-long drought. But drug development is a slow process, and the only compounds far enough along in the pipeline to quickly replace current ACTs are variations on the artemisinin theme. Whether they will kill resistant parasites is a big question.